PharmaResearch, a leader in regenerative medicine, announced its initiatives to enhance academic marketing efforts around its key aesthetic lineup, including 'Rejuran', 'Evercle', and 'Rejuderma', on the 22nd.
The company aims to elevate the understanding of its products among healthcare professionals through scholarly activities that share scientific principles and clinical experiences. These initiatives focus on discussing various applications of products in clinical settings, effectively communicating clinical considerations tailored to each product's characteristics and intended treatments. As part of this effort, PharmaResearch participated in the Korea Society of Aesthetic Medicine (KOAT) and the Korean Society of Aesthetic Functional Medicine's (KFCC) fall academic conference, showcasing lectures related to its major aesthetic products.
At the KOAT conference held on the 18th, experiences regarding the clinical application of 'Rejuran' and 'Evercle' were shared. Kyung-Hwan Lee, a co-director of KOAT and the head of Project You Clinic, delivered a lecture titled 'The Evolution of Skin Rejuvenation: Designing Synergy Protocols with DOT PN and PLLA’. The presentation highlighted the characteristics of 'Rejuran', based on PN with DOT® technology, and PLLA-based biostimulant 'Evercle', discussing clinical considerations for skin rejuvenation and procedural insights.
During the KFCC conference on the same day, lectures covering the scientific principles and clinical applications of 'Rejuran', 'Evercle', and 'Rejuderma' were conducted. Michael Kim, Executive Director of PharmaResearch's Medical Strategy Division, presented on 'The Evolution of DOT Poly Nucleotide (Rejuran): Structural Distinctions with Scaffold Structure and PDRN'. Dr. Hyun-Joon Park from Meilin Clinic discussed the aesthetic functional medical value and clinical applications of PLLA-based Evercle, while Dr. Won-Wook Hwang from Cheongdam Rabel Clinic introduced a functional medical approach to skin barrier damage and the recovery mechanisms through Rejuderma. Additionally, Dr. Kyung-Min Park from Seongsu Melting Clinic explored strategies to preserve lean body mass during GLP-1 therapy using placental extracts.
PharmaResearch plans to continue its academic activities across its aesthetic portfolio, focusing on communicating product characteristics and delivering clinical experiences. The company emphasizes enhancing scholarly exchanges that reflect the practical experiences and feedback from healthcare providers.
A PharmaResearch spokesperson stated, “We are pleased to convey the excellence and clinical value of our regenerative medicine-based aesthetic portfolio to medical professionals through various domestic conferences. We will continue to foster understanding of our key products like Rejuran, Evercle, and Rejuderma, while focusing on expanding scholarly exchanges that share diverse experiences from actual clinical settings.”
